| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514300100 | Glycopeptide utilizing | 35 |
| 20100261639 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE - Aminoglycoside-amino acid and -peptide conjugates comprising a triazolyl linker are provided along with efficient methods of their preparation. The aminoglycoside may be an aminoglycoside antibiotic. Conjugates comprising an aminoglycoside antibiotic may exhibit antimicrobial activities against Gram-positive and/or Gram-negative strains and display significantly enhanced activity against multi-drug resistant MRSA and MRSE when compared to their unconjugated aminoglycoside antibiotic counterparts. | 10-14-2010 |
| 20100267624 | VANCOMYCIN AND TEICOPLANIN ANHYDROUS FORMULATIONS FOR TOPICAL USE - The invention concerns pharmaceutical anhydrous formulation for topical use comprising Vancomycin, Vancomycin Hydrochloride, or Teicoplanin, and Dimethylsulfoxide. In a preferred embodiment the formulation further comprises one or more glycols and/or ethers thereof, and optionally one or more fatty acids triglycerides and/or the polyoxyethylene derivative thereof. The use of Dimethylsulfoxide in anhydrous formulation for topical use leads to formulations characterized by high homogeneity and high concentration, if desired, of Vancomycin, Vancomycin Hydrochloride, or Teicoplanin. These Dimethylsulfoxide-containing formulations are also very stable in time. | 10-21-2010 |
| 20100286031 | Antibiotic Formulations, Unit Doses, Kits and Methods - An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods. | 11-11-2010 |
| 20100311646 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of | 12-09-2010 |
| 20110015119 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections. | 01-20-2011 |
| 20110021417 | COMPOSITIONS COMPRISING OLIGOSACCHARIDES - The present invention concerns compositions comprising a saccharide for the inhibition of pathogen adhesion to mammalian cells. | 01-27-2011 |
| 20110046041 | METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS - The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin. | 02-24-2011 |
| 20110086797 | CONTROL OF SPORE GERMINATION - Provided are compositions and methods for treating bacterial infections. It is demonstrated herein that bacteria cell wall materials stimulate germination of spores of Gram-positive bacteria, and that such activity requires Ser/Thr kinase PrkC. By modulating one or both, spores (which can be antibiotic resistant) can be stimulated or inhibited from germination, which can be exploited in various methods of therapeutic treatment. Also provided is a method of modulating germination of a spore of a Gram-positive bacterium. Also provided is a method of decontaminating an environment. | 04-14-2011 |
| 20110152177 | Functional Feed Composition - A feed composition comprising conventional feed ingredients, peptidoglycan and nucleotides is described. The feed composition can be used to prevent or reduce infectious diseases, and prevent symptoms related to an infectious disease in an animal. There is also provided a method for feeding of fish by providing this feed composition in the period previous of the challenge by an infection, during the infection or after the infection. | 06-23-2011 |
| 20110207659 | OLIGOSACCHARIDE COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF INFECTION - Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described. | 08-25-2011 |
| 20110224130 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS - This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. | 09-15-2011 |
| 20110301078 | PREVENTION OF BACTERIAL GROWTH AND BIOFILM FORMATION BY LIGANDS THAT ACT ON CANNABINOIDERGIC SYSTEMS - A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant | 12-08-2011 |
| 20120149632 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY - The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections. | 06-14-2012 |
| 20120202738 | THERAPY FOR ENTERIC INFECTIONS - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 08-09-2012 |
| 20120289457 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES - Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects. | 11-15-2012 |
| 20130190227 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH - Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal. | 07-25-2013 |
| 20130274175 | TREATMENT OF DISEASE ASSOCIATED WITH THE USE OF ANTIBIOTICS - This invention relates to the treatment or prevention of diseases associated with the use of antibiotics or cancer chemotherapies or antiviral therapies, such as colitis, pseudomembranous colitis, antibiotic associated diarrhea and infections due to | 10-17-2013 |
| 20130310308 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of | 11-21-2013 |
| 20130316943 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and their methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent. | 11-28-2013 |
| 20140005099 | MARKERS FOR DIAGNOSIS OF PULMONARY INFLAMMATION AND METHODS RELATED THERETO | 01-02-2014 |
| 20140080754 | DIAGNOSTIC METHOD FOR BACTERIAL MENINGITIS - It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis. | 03-20-2014 |
| 20140155320 | USE OF STORAGE STABLE VISCOUS PHOSPHOLIPID DEPOT TO TREAT WOUNDS - The present invention provides a method of preventing and/or treating a wound infection by introducing to a wound a clear depot comprising a hydrophilic water-soluble pharmaceutically active agent(s) selected from the group consisting of vancomycin, gentamicin, and a mixture thereof, water, a phospholipid, an oil, a pH adjusting agent, and a viscosity modifying agent, wherein the water present in the viscous depot is no more than about 4 wt %, no more than about 2 wt %, or no more than about 0.5 wt % of water relative to the total weight of the depot. | 06-05-2014 |
| 20140162941 | PROCESS FOR PREPARING BIOLOGICAL SAMPLES - Methods and compositions for preparation of a sample, including a sample to be analyzed for the presence of one or more pathogens. Transport of a non-diluted sample from an individual suspected of having the pathogen and transfer of the sample directly into a nucleic acid extraction buffer occurs in a single step. The process is an improvement over known methods because it provides accurate, rapid analysis that utilizes fewer steps and/or reagents from methods used in the art. In specific embodiments, it has one or more of the following characteristics: 1) it is a one-step process; 2) it eliminates dilution of the sample; 3) smaller sample sizes are employed; 4) fewer reagents are utilized; 5) transport media is not required; 6) less than 1 colony forming unit is required for detection; 7) fast; and 8) economic. | 06-12-2014 |
| 20140171359 | DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASES USING URINE SPECIMENS - Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication. | 06-19-2014 |
| 20140200175 | SUPPRESSION OF TOXIN PRODUCTION OF CLOSTRIDIUM DIFFICLE - Disclosed in an embodiment herein is a method of treating symptoms of | 07-17-2014 |
| 20140213507 | DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASE USING BLOOD SPECIMENS - Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in which a measured value of sCD14-ST in blood is used as an indication. | 07-31-2014 |
| 20150148287 | CATHETER LOCK SOLUTION FORMULATIONS - A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as glycerol, polysorbate-20, or polyethylene glycol (PEG)-400, along with a lower alcohol, such as ethanol, and an anti-coagulant, such as tri-sodium citrate, antibiotic, and/or anti-microbial. | 05-28-2015 |
| 20160022702 | METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN - Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 01-28-2016 |
| 20160046576 | NOVEL PYRROLE DERIVATIVES - There are provided inter alia compounds of formula (I) | 02-18-2016 |
| 20160082143 | Method for Producing an Antibiotic Polymethylmethacrylate Bone Cement Powder, and an Antibiotic Polymethylmethacrylate Bone Cement Powder - The invention relates to a method for producing an antibiotic bone cement, whereby, in a step A), a bone cement base powder with a water content of less than or equal to 1.0% by weight is mixed with trometamol-fosfomycin to form a bone cement powder, and, in a step X), the bone cement powder is dried to a water content of less than or equal to 1.0% by weight. The invention also relates to a bone cement powder that was produced according to said method and contains a bone cement base powder and trometamol-fosfomycin, whereby the bone cement powder has a water content of less than or equal to 1.0% by weight. The bone cement powder is free-flowing and does not clump and can be used for producing bone cements that meet ISO 5833. | 03-24-2016 |
| 20160131649 | MICROBIAL GLYCANS AS A TARGET OF HUMAN INTELECTIN - The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including | 05-12-2016 |
| 20160145266 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE - Disclosed are compounds of formula (I): | 05-26-2016 |
| 20160161506 | DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASE USING BLOOD SPECIMENS - Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in which a measured value of sCD14-ST in blood is used as an indication. | 06-09-2016 |
| 20160169889 | DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASE USING URINE SPECIMENS | 06-16-2016 |
| 20220133845 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF - The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof. | 05-05-2022 |
